Myelofibrosis: Symptoms, Diagnosis, and Treatment Landscape

Disease Overview

Primary myelofibrosis (PMF) is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal hematopoiesis, bone marrow fibrosis, extramedullary hematopoiesis, and cytokine-driven constitutional symptoms.

Common Presenting Features

  • Anemia (fatigue, exertional dyspnea)
  • Splenomegaly (early satiety, left upper quadrant pain)
  • Constitutional symptoms: night sweats, weight loss, low-grade fever, pruritus
  • Leukocytosis or leukopenia; thrombocytosis or thrombocytopenia
  • Bone pain, gout (hyperuricemia)

Diagnostic Criteria (WHO 2022)

  • Megakaryocyte proliferation and atypia plus reticulin/collagen fibrosis (grade 2–3).
  • Driver mutation: JAK2 V617F (~60%), CALR (~25%), MPL (~5%), or "triple-negative".
  • Exclusion of other myeloid neoplasms.

Risk Stratification

Prognostic scores (IPSS, DIPSS-plus, MIPSS70+) incorporate age, hemoglobin, leukocytes, blasts, symptoms, karyotype, and mutation profile to guide transplant timing.

Treatment Options

  • JAK inhibitors: Ruxolitinib (first-line for symptomatic splenomegaly/cytopenias), fedratinib, pacritinib, momelotinib.
  • Allogeneic stem cell transplant: Only potentially curative; reserved for higher-risk, transplant-eligible patients.
  • Supportive care: Transfusions, erythropoiesis-stimulating agents, androgens, splenectomy/radiation for refractory splenomegaly.
  • Clinical trials: Novel JAK inhibitors, BET inhibitors, anti-fibrotics, immunotherapy.

Management is individualized; early referral to an MPN center optimizes outcomes.

Blood Disorders - Related Articles